EntryPoint Capital LLC Buys 19,862 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

EntryPoint Capital LLC raised its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 214.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 29,144 shares of the company’s stock after purchasing an additional 19,862 shares during the period. Castle Biosciences comprises 0.3% of EntryPoint Capital LLC’s portfolio, making the stock its 14th largest holding. EntryPoint Capital LLC’s holdings in Castle Biosciences were worth $777,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of CSTL. R Squared Ltd bought a new stake in Castle Biosciences during the fourth quarter valued at about $42,000. Quest Partners LLC lifted its position in Castle Biosciences by 54.4% in the third quarter. Quest Partners LLC now owns 4,318 shares of the company’s stock worth $123,000 after buying an additional 1,522 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Castle Biosciences during the fourth quarter valued at approximately $128,000. Point72 DIFC Ltd purchased a new position in Castle Biosciences in the 3rd quarter worth about $140,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Castle Biosciences by 11.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,939 shares of the company’s stock worth $158,000 after buying an additional 604 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Insider Activity at Castle Biosciences

In related news, Director Daniel Bradbury sold 7,867 shares of the stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $28.17, for a total value of $221,613.39. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Derek J. Maetzold sold 986 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $28.03, for a total value of $27,637.58. Following the completion of the sale, the insider now owns 80,818 shares of the company’s stock, valued at $2,265,328.54. This trade represents a 1.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 44,204 shares of company stock valued at $1,055,988 over the last three months. 7.20% of the stock is owned by insiders.

Castle Biosciences Trading Up 2.2 %

NASDAQ CSTL opened at $20.98 on Tuesday. The firm has a market capitalization of $587.59 million, a price-to-earnings ratio of 104.91 and a beta of 0.98. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.64 and a current ratio of 7.78. Castle Biosciences, Inc. has a one year low of $16.97 and a one year high of $35.84. The company’s 50 day moving average price is $24.59 and its 200 day moving average price is $28.25.

Analyst Ratings Changes

CSTL has been the topic of several research analyst reports. Robert W. Baird boosted their target price on Castle Biosciences from $36.00 to $37.00 and gave the stock an “outperform” rating in a research note on Friday, February 28th. Stephens reissued an “overweight” rating and issued a $41.00 price target on shares of Castle Biosciences in a report on Thursday, January 2nd. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Castle Biosciences presently has an average rating of “Buy” and an average price target of $40.00.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.